Monday, December 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

AMD Stock: Mixed Results Amid China Export Woes

Robert Sasse by Robert Sasse
August 6, 2025
in Stocks
0
AMD Stock
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

AMD reported strong Q2 2025 revenue growth of 32% year-over-year, reaching $7.69 billion, surpassing analyst expectations of $7.42 billion. However, after-hours trading saw shares drop over 6% to $163.37 as investors hoped for even better performance. While adjusted earnings per share met forecasts at $0.48, U.S. export restrictions to China weighed heavily, forcing $800 million in write-downs and slashing gross margins from 53% to 43%.

Data Center Growth Offset by Gaming Surge

The data center segment grew 14% to $3.2 billion, driven by strong demand for EPYC server processors, but posted a $155 million operating loss due to China-related setbacks. In contrast, the client and gaming division soared 69% to $3.62 billion, fueled by record sales of Ryzen processors and GPUs. For Q3, AMD projects revenue of $8.7 billion, above estimates, with margins expected to rebound to 54%, though China uncertainties linger.

Ad

AMD Stock: Buy or Sell?! New AMD Analysis from December 22 delivers the answer:

The latest AMD figures speak for themselves: Urgent action needed for AMD investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 22.

AMD: Buy or sell? Read more here...

Tags: AMD
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Infineon Stock

Infineon Stock: Mixed Signals Amid Market Volatility

Kontron Stock

Kontron Stock: Strategic Shift Boosts Margins Amid Sales Dip

Siemens Energy Stock

Siemens Energy Stock: Record Orders Fuel Turnaround Hopes

Recommended

FCBC stock news

Krane Funds Advisors LLC Acquires Stake in Avista Co. and Highlights Lucrative Dividend Opportunity in Utilities Sector

2 years ago
Synopsys Stock

Synopsys Shares Face Mounting Pressure as Confidence Falters

3 months ago
Stryker Stock

Stryker Shares Face Market Pressure Despite Strong Fundamentals

1 month ago
Confluent Stock

Confluent Shares Surge as Artificial Intelligence Demand Accelerates

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Textron Stock Approaches Annual Peak Amid Strategic Wins

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

Strategy Inc. Faces a Critical Index Classification Decision

DeFi Technologies Broadens Global Reach with New Listings and Products

Barrick Gold Secures Key Resolution in Mali, Paving Way for Mine Restart

Analyst Upgrade Sends Red Cat Shares Soaring

Trending

Alphabet Stock
AI & Quantum Computing

Alphabet’s AI Strategy Gains Momentum with New Model and Major Deals

by Dieter Jaworski
December 22, 2025
0

Alphabet Inc. has launched its latest strategic move in the competitive artificial intelligence arena with the introduction...

Tesla Stock

Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push

December 21, 2025
Wolfspeed Stock

Wolfspeed Secures Financial and Strategic Milestones

December 21, 2025
Textron Stock

Textron Stock Approaches Annual Peak Amid Strategic Wins

December 21, 2025
Intellia Therapeutics Stock

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

December 21, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Alphabet’s AI Strategy Gains Momentum with New Model and Major Deals
  • Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push
  • Wolfspeed Secures Financial and Strategic Milestones

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com